Managment of diabetic ketoacidosis in children and adolescents in sub-Saharan Africa: A review by Majaliwa, EJ et al.
April 2010 EAST AFRICAN MEDICAL JOURNAL   167
INTRODUCTION
Diabetic ketoacidosis (DKA) has been recognised 
as the main complication and potentially fatal 
emergency in children and adolescents with type 
1 diabetes mellitus (T1DM) (1). Definition of DKA 
includes hyperglycaemia (blood glucose > 11 mmol/
L [~200 mg/dL]), venous pH <7.3 or bicarbonate <15 
mmol/L, in association with ketonemia, ketonuria 
and glycosuria; occasionally some patients present 
with normal glycaemic ketoacidosis (2). A decrease 
in serum insulin and a glucoregulatory hormones 
imbalance, causing hyperglycaemia, lipolysis 
and acidosis, are responsible for developing DKA 
(1). DKA occurs all over the world with reported 
frequency rates higher in developing countries 
than in the industrialised world. Frequencies of 
DKA range from 15 to 70% in Europe, Australia 
and North America (3-5). The prevalence rate of 
diabetes continues to grow in all Western nations 
(6), however the prevalence of DKA has remained 
low, principally following prevention programmes 
(7). In developing countries, specifically sub-Saharan 
Africa very little primary data exist on T1DM and 
most information depends on anecdote. The few data 
available estimate the incidence to be 1.5/100,000 
in Tanzania (8), an increase in incidence from 
9.5/100,000 in 1991 to 10.3/100,000 in 1995 in Sudan 
(9), with the prevalence of DKA ranging between 
42 to 76% (10,11). 
 Most healthcare workers are not able to recognise 
symptoms and signs of DKA in sub-Saharan Africa, 
which contributes to high rates of DKA at presentation 
(12). In fact the report by International Insulin 
Foundation in three African countries, found that 
many doctors were scared of insulin and diabetes, 
and the only training on diabetes they have ever 
had was during their university education (13). In 
contrast it was found that the same health workers 
were able to recognise all other common diseases in 
their setting with the resources they have, reflecting 
the little importance given to diabetes. 
 DKA at diagnosis is more common in younger 
children (<5 years of age) and in children whose 
families do not have readily access to medical care 
for social or economic reasons (14), lower income and 
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ABSTRACT
Background: Diabetic ketoacidosis (DKA) is a complex metabolic state of hyperglycaemia, 
ketosis, and acidosis. Diabetes in sub-Saharan Africa is, in many patients a serious disease 
with a poor prognosis. Most deaths, however, are due to preventable causes. 
Objective: To improve knowledge on the management of DKA in sub-Saharan Africa.
Data sources: Literature review from different published sources. 
Data synthesis: Health systems in sub-Saharan Africa are currently organised for the 
treatment of episodes of illness and not long-term conditions like diabetes. Therefore 
the high rates of DKA is essentially due to lack of training of health professionals, 
lack of facilities in most hospitals, lack of public awareness as well as lack of health 
education to individual patients/families. In addition erratic insulin supply coupling 
with infections, low parental education, poor insulin storage and lack of facilities for 
self monitoring of blood glucose. 
Conclusion: A complex unfavourable social and economic environment is the basis 
of the high prevalence of DKA in sub-Saharan Africa. Several episodes of DKA can 
be prevented by effective public awareness programmes and education to healthcare 
providers. 
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lack of health insurance (15). Prevalence of DKA at the 
time of diagnosis in sub-Saharan Africa was found to 
be between 70 to 80% (13, 14). Due to lack of health 
care workers training and facilities for diagnosis, 
many children might be misdiagnosed as malaria or 
meningitis in a busy emergency department of many 
hospitals in sub-Saharan Africa (16). 
 DKA after diagnosis in western countries is in 
the range of 16 to 36% (6), in contrast to the rates in 
Africa which are as high as 76% (11). These high rates 
are attributable to erratic insulin supply coupling with 
infections (11, 14, 17), low parental education, poor 
insulin storage as well as lack of facilities for blood 
glucose monitoring. 
 The mortality due to DKA in Europe is well 
below 5% (18, 19) yet in sub-Saharan Africa there 
has been no reported reduction in mortality 
rates, stressing further the importance of diabetes 
awareness, reliable insulin supply and availability of 
glucose monitoring facilities, both in hospitals and 
to individual patients. 
 Strategies are essential for prediction, prevention 
and successful treatment of DKA in infants, 
children, and adolescents. Therefore, strategies for 
management of DKA and its complications in children 
and adolescents with T1DM are essential. Since there 
is very little known on T1DM in sub-Saharan Africa 
this paper aims to review the main aspects of the 
management and prevention of DKA in children and 
adolescents in sub-Saharan Africa. 
PATHOPHYSIOLOGY OF DKA
Several metabolic alterations are responsible for 
developing DKA. The primary cause is insulin 
deficiency, which may be precipitated by infection 
or other forms of stress. The subsequent increase 
of glucoregulatory hormones leads to an increased 
hepatic glyconeogenesis and glycogenolysis leading 
to an high release of glucose, as well as proteins 
and fat from muscle and adipose tissues. These 
metabolic events lead to increased lipolysis and ketone 
production with the end result of hyperglycaemia, 
ketonemia, increased plasma osmolarity and kidney 
glycaemic load. As hyperglycaemia exceeds the renal 
threshold, it leads to osmotic diuresis, electrolyte loss, 
and eventually dehydration. The subsequent reduced 
kidney function is responsible for retention of glucose 
and increased plasma anion gap. 
 DKA is generally categorised by the severity of 
the acidosis, varying from mild DKA (venous pH: 
<7.30 and/or bicarbonate concentration <15 mmol/
L), moderate DKA (pH: <7.2 and/or bicarbonate: 
<10mmol/L) to severe DKA (pH: <7.1, and/or 
bicarbonate: <5 mmol/L) (2, 20). 
MANAGEMENT STRATEGIES
Management of DKA needs to be prompt and helpful 
to correct metabolic abnormalities. One should 
identify and treat the precipitating factors and co-
morbid conditions, set appropriate longterm plan to 
prevent recurrence and intend to maintain adequate 
diabetes control. The therapeutic goals consist of 
replacement of insulin to lower hyperglycaemia and 
reverse ketogenesis, fluid and electrolyte replacement 
to correct dehydration and metabolic acidosis 
and management of precipitating or co-morbid 
conditions. It is necessary to perform a complete and 
meticolous physical evaluation to establish gravity 
of patient’s status and its underlying pathogenesis 
(major components are insulinopenia, infection or 
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Treatment consists primarily of insulin administration 
and replacement of fluid and electrolytes  (Table 3). 
Likewise prevention hinges on avoiding insulin 
deficiency by regular use of insulin for control of glucose 
and compensation for stress. Because of the metabolic 
derangements of DKA, some laboratory tests can be 
misleading and need to be carefully interpreted. 
 Since in sub-Saharan Africa one of the most 
common causes of DKA is infections like pneumonia, 
malaria, UTI and tuberculosis, screening for infections 
should be done (1). 
 TREATMENT
Assessment of the clinical status of the child, laboratory 
investigations and electrographic monitoring need to 
be regularly performed: hourly or more frequently if 
required (Tables 1 and 2). However fluid input and 
output should be assessed. 
Fluid and electrolyte therapy: The first measure towards 
restoration of fluid and electrolyte deficit is to start 
venous infusion on the basis of estimated dehydration 
level (Table 3). 
Table 2
Assessment of dehydration status (21)
 Mild Moderate  Severe 
% weight  3-5 5-9 10
Mg/kg  30-50 50-90 100
Heart rate  N  
Blood pressure N  
Behaviour  N Irritable Lethargic
Mucous membrane  N Dry Very dry
Tears  Present  Absent
Skin tugor  N  Cold cyanotic
N= Normal,  =Reduced,  =Increased 
(i) Initially normal saline (0.9%Nacl) or Ringer’s 
lactate. 
(ii) Use of colloids is not necessary. 
(iii) Later, a hypotonic solution should be provided 
(0.45% NaCl) to avoid excessive increase of 
serum sodium concentration. 
(iv) Amount of fluid must be given evenly over 48 
hours, (21) 
(v) The most recommended formulas to obtain 
the corrected sodium are: measured Na + 2 
x [(glucose mmol/1 - 5.6) / 5.6] or Na + 2 x 
[(glucose mg/dl - 100) / 100]. As known, serum 
electrolytes, determination of osmolality and 
anion gap could be helpful to assess doses and 
duration of fluid and electrolyte therapy. 
(vi) Oral fluids should be started when the patient 
feels good, the clinical condition is getting better 
and the patient is able to drink. 
(vii) Oral fluid volume should be subtracted from 
intravenous intake. 
Insulin 
(i)  After beginning initial rehydration, intravenous 
insulin infusion is fundamental in order to 
restore homeostasis and stop further ketone 
production. 
Table 3
Fluid and electrolyte (21)
Weight  0-10 kg 10.1-20 kg >20 kg   
Fluid 100 ml/kg 1000 ml + 50 ml/kg 1500 ml + 20 ml   
  per every kg > 1 0 kg    per every kg >20 kg   
Sodium 3 mEq/kg 3 mEq/kg 3 mEq/kg   
Potassium 2 mEq/kg 2 mEq/kg 2 mEq/kg   
Chloride 5 mEq/kg  5 mEq/kg 5 mEq/kg  
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(ii) If the patient is in shock it is not indicated to 
start insulin until resolved 
(iii) In other cases, insulin should be started 1-2 
hours after beginning rehydration (22) at a dose 
of 0.1 unit/kg/hour (some recommend 0.05 
units/kg/hour particularly for younger patients 
<10 kg). This dose should reduce glycaemia and 
continued until correction of acidosis (23). 
(iv) If blood glucose is decreasing too fast the dose of 
insulin should be reduced to 0.05 U/kg/hour. 
(v) When the blood glucose is between 14-17 
mmol/l insulin rate should be dropped by half 
and change the infusion to saline solution’ and 
added glucose. 
(vi)  When syringe pumps for insulin are not available 
a separate low-dose infusion may be given, as 
soluble insulin 50 units in 500 ml normal saline 
solution at a dose of 0.1 unit/kg/hr (24). 
(vii) When it is not possible to perform infusion, hourly 
1M injections of soluble or rapid-acting insulin 
0.1 units/kg has been used helpfully (25).
(viii) Subcutaneous insulin should be started when 
ketoacidosis has resolved, the patient is well 
hydrated and patient can eat: the best approach is 
changing to subcutaneous insulin before a meal. 
(ix)  Subsequently, continue to monitor glycaemia 
levels on regular basis and titrate insulin dose 
with glucose levels. 
 In c ircumstances where intravenous 
administration is not possible and in a patient with 
uncomplicated DKA, hourly or after two hours 
intramuscular administration of short or rapid acting 
insulin analogs (Insulin lispro or insulin aspart) have 
been used effectively (26). This regimen can be used in 
ambulatory patients where hospitalisation is costly. 
Potassium: Reduced potassium is a common feature 
of ketoacidosis, related to prolonged duration of 
evolution of DKA, deficit of 3 to 6 mmol/kg (27). It 
is unusual to find normal or high potassium at the 
time of presentation due to the passage of intracellular 
potassium into the intravascular space masking the 
actual reduction of the electrolyte. After starting 
insulin therapy and improvement of acidosis, there 
is a progressive return of potassium into the cells 
causing hypokalaemia. If serum potassium is not 
available before the completion of resuscitation, 
ECG monitoring is recommended before potassium 
is added to infusion fluid. Flattening of the wave, 
widening of the QT interval, and the appearance of 
U waves indicate hypokalaemia, while tall, peaked, 
symmetrical T waves and shortening of the QT 
interval are signs of hyperkalaemia. 
(i)  In hypokalaemic patients, potassium 
administration as slow infusion should start 
immediately, before initiation of insulin therapy. 
(ii) In normokalaemic patients, potassium 
replacement is recommended after the first or 
second hour of treatment. 
(iii) In hyperkalaemic patients, potassium 
replacement is delayed until urine output is 
documented. 
(iv) The dose of potassium (KCL) is 4-10 mmol/hr 
in the initial infusion and continues throughout 
the parenteral infusion (the maximum 
recommended rate of intravenous potassium 
replacement is usually 0.5 mmol/kg/hour). 
Overzealous potassium replacement should 
be avoided where monitoring is not close. 
Sodium: If serum osmolality fails to rise, and 
particularly if it falls, careful re-evaluation of fluid 
replacement is required. Consideration to increase 
the concentration of sodium chloride is important 
at this point, however increased vigilance for signs 
of cerebral oedema is extremely important. The 
physiological saline will correct the sodium deficit, 
however: 
(i)  if the serum sodium is <140 mEq/l: 0.9% NaCI 
should be used. 
(ii) if the serum sodium is >140 mEq/l: 0.45% NaCI 
should be used. 
Phosphate: Adverse complications of hypophosphatemia 
are uncommon and occur primarily in patients with 
severe hypophosphatemia [a serum phosphate 
concentration of less than 1.0 mg per dL (0.32 
mmol per L)] (28). There is no clinical benefit for 
phosphate replacement in the treatment of DKA, and 
excessive phosphate replacement may contribute to 
hypocalcaemia and soft tissue calcification (29). 
Acidosis and sodium bicarbonate replacement: Usually 
severe acidosis is reversed by fluid and insulin 
replacement. Insulin stops further ketones 
production and allows ketoacids to be metabolised, 
which generates bicarbonate. 
By treating hypovolaemia, tissue perfusion 
is improved hence improvement of renal function 
with consequent increase in excretion of organic 
acids. Regarding use of sodium bicarbonate, there 
are exceptional cases where there is a clear indication 
to perform bicarbonate infusion. Nevertheless, there 
may be selected patients who may benefit from 
bicarbonate therapy. These include patients with 
severe acidemia (arterial pH <6.9) (30), and those 
with life-threatening hyperkalaemia. Cautious 
administration of 1-2 mmol/kg over 60 min may 
suffice. 
To monitor carefully DKA progress and its 
management, it can be helpful to use the following 
diary (Figure 1). 




Cerebral oedema: Cerebral oedema is one of the 
most dreadful complications of DKA in children 
that require a prompt recognition to reduce related 
mortality or irreversible neurological damages. 
Mortality estimates vary widely, but some authors 
suggest that the disorder is lethal in about 20 to 50% 
of patients, particularly children (31). Fortunately, it 
is a rare occurrence, complicating about 0.5 to 0.9% 
of cases of DKA (32). 
The pathogenesis of this complication may 
be complex. A number of mechanisms have been 
proposed including the role of cerebral ischaemia/
hypoxia and the generation of various inflammatory 
mediators (33,34), increased cerebral blood flow 
(35), disruption of cell membrane ion transport 
(36) and aquaporin channels (37). The generation 
of intracellular organic osmolytes (myoinsoitol, 
taurine) and subsequent cellular osmotic imbalance 
have also been implicated (38). Furthermore, 
high glycaemia and serum sodium levels cause 
contraction of cell volume due to a fluid shift from 
the intracellular to the extracellular compartment. 
By starting therapy, decline in serum osmolality 
reverses this mechanism with rapid expansion of 
cerebral intracellular volume causing successive 
cell swelling and raised intracranial pressure (21). 
Typically, symptomatic cerebral oedema 
occurs 4-12 hours after the initiation of therapy but 
cases have also occurred before initiation of therapy 
(39) and as late as 24-28 hours after the initiation of 
treatment (40) (Table 4). 
Management of cerebral oedema: 
(i)  Intravenous mannitol should be given at the 
dose of 0.25-1.0 g/kg over 20 minutes; repeating 
the infusion if there is no response within two 
hours. 
(ii)  An hypertonic saline solution (3%) at the dose of 
5-10 ml/kg over 30 minutes, can be used instead 
of mannitol (40). 
(iii)  Elevation of the patient’s head is necessary 
to favour venous blood return and reduce 
intracranial pressure. 
(iv)  Intubation and ventilation may be necessary. 






















































































Signs and symptoms of cerebral oedema (21,31)
Risk factors for cerebral oedema  Signs and symptoms of cerebral oedema
• Age <5 years due to immaturity of auto- • Sudden onset of headache 
  regulatory systems • Vomiting, blurring of vision
• Children with newly diagnosed T1DM • Bradycardia postural hypotension 
• Prolonged duration of metabolic derangements • Circulatory compromise
• Severe acidosis and low pCO2 • Respiratory failure 
• Failure of sodium ions to rise as predicted    • Decreased level of consciousness 
 • Papilloedema seizures and coma
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Table 5
Other complications of DKA
Pulmonary complications (oedema, aspiration 
pneumonia,) 
Hypokalaemia or 
hyperkalaemia Cardiac arrhythmias 
Peripheral venous 
thrombosis  Brain injuries 
Secondary sepsis  Rhabdomyolysis 
Acute pancreatitis  Acute renal failure 
STRATEGIES FOR SUCCESSFUL 
PREVENTION OF DKA
DKA represents a serious metabolic derangement 
that requires special strategies to reduce its mortality 
and severe sequelae. At present, there is evidence of a 
wide difference between developed and developing 
countries in terms of mortality of patients with 
T1DM. In fact, in the industrialised world children 
unusually die of ketoacidosis, while in developing 
countries this emergency is common and carriers a 
high mortality. In sub-Saharan Africa, in particular, 
there are many problems regarding diabetic patients, 
because of the absence of an effective management 
system for diabetes including timely recognition of 
its complications and prevention. 
Prevention before diagnosis
(i)  Education aimed at raising the awareness of 
symptoms of diabetes is essential in order to 
prevent DKA in newly presenting TlDM (11). 
(ii)  Effective public awareness programmes on 
symptoms and signs of DKA, like information 
by the mass media, posters displayed in primary 
and secondary public schools as well as public 
places. 
(iii) Training of healthcare workers on diagnosis of 
TlDM, DKA and their management. 
(iv) Use of uristicks to investigate glycosuria in case 
of suspected diabetes. 
Prevention after diagnosis 
(i)  For prevention of DKA in established TlDM, the 
primary issue should be optimal glucose control 
with insulin and prompt intervention in cases 
of metabolic decompensation. 
(ii) It is essential to guarantee a dedicated diabetes 
care staff for children with diabetes and functional 
monitoring instruments., 
(iii) It is necessary to have not only regular and 
reliable insulin but also instruments of delivery 
like syringes and needles. 
(iv) Parents should have an appropriate health 
education and be effectively trained about how 
to manage diabetes at home especially when 
children get ill, in case of infections or other 
situations which could lead to DKA. 
(v) Patients should also be trained about how to 
prevent DKA or recognise mild forms of DKA as 
soon as possible to avoid progression to severe 
DKA. 
CONCLUSION
There may be an increase in the prevalence of 
TlDM in children in sub-Saharan Africa, increased 
awareness of presentation and knowledge of 
the pathophysiology and management of DKA 
is imperative. Several episodes of DKA can be 
prevented by effective public awareness programmes 
and education to healthcare providers. Therefore, 
there is an underlined need to inform both physicians 
and public in order to take up the challenge of 
reducing the incidence of DKA. Efforts at making 
insulin available and home monitoring of blood 
glucose accessible are imperative if the prevalence 
of DKA is to be reduced and optimise metabolic 
control of childhood diabetes. Collaboration of 
governmental and non-governmental agencies 
in ensuring availability of insulin and other 
consumables in diabetes care will also go a long way 
to improve the outcome of children with T1DM. 
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